Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders

Veterinary Clinics of North America - Small Animal Practice

Volumn 34, Issue 1, 2004, Pages 67-172

  Center, Sharon A ^a  

^a Department of Molecular Biology and Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; ANTIOXIDANT; ASCORBIC ACID; COPPER; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; GLUTATHIONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; PENTOXIFYLLINE; PHOSPHATIDYLCHOLINE; PROBIOTIC AGENT; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; S ADENOSYLMETHIONINE; SALICYLIC ACID; SILIBININ; SILYBUM MARIANUM EXTRACT; SILYMARIN; THIOCTIC ACID; THIOL DERIVATIVE; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA; UBIQUINONE; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VALPROIC ACID; ZINC;

AGITATION; ALTERNATIVE MEDICINE; ANIMAL CELL; APOPTOSIS; BIOLOGICAL THERAPY; CELL DEATH; CLINICAL TRIAL; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATOBILIARY DISEASE; HERBAL MEDICINE; HUMAN; HUMAN CELL; HYPOGLYCEMIA; KUPFFER CELL; LIVER FIBROSIS; LIVER INJURY; LIVER MITOCHONDRION; MANIA; NONHUMAN; OBSTRUCTIVE JAUNDICE; OXIDATIVE STRESS; PROTEIN FUNCTION; RAT; REVIEW; SEPSIS; SEROTONIN SYNDROME; SKIN ALLERGY; STELLATE CELL;

ANIMAL DISEASES; ANIMALS; ANTIOXIDANTS; APOPTOSIS; COMPLEMENTARY THERAPIES; HEALTH FOOD; LIVER DISEASES; PLANT EXTRACTS; PROBIOTICS; TREATMENT OUTCOME; VETERINARY MEDICINE;

ANIMALIA; SILYBUM MARIANUM;

EID: 0742288763     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2003.09.015     Document Type: Review

References (502)

1. Hrobjartsson A. Gotzsche P.C. Is the placebo powerless? An analysis of clinical trials comparing placebo treatment with no treatment N Engl J Med 344 2001 1594-1604
2. Kaplowitz N. Mechanisms of liver cell injury J Hepatol 32 2000 39-47
3. Jaeschke H. Gores G.J. Cederbaum A.I. et al. Mechanisms of hepatotoxicity Toxicol Sci 65 2002 166-176
4. Jaeschke H. Inflammation in response to hepatocellular apoptosis Hepatology 35 2002 964-966
5. Kaplowitz N. Tsukamoto H. Oxidative stress and liver disease Prog Liver Dis X1V 1996 131-159
6. Lemasters J.J. Nieminen A.L. Qian T. et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophage Biochim Biophys Acta 1366 1998 177-196
7. Lemasters J.J. The mitochondrial permeability transition: from biochemical curiosity to pathophysiological mechanism Gastroenterology 115 1998 783-786
8. West M.A. Keller G.A. Cerra F.B. et al. Killed Escherichia coli stimulate macrophage-mediated alterations in hepatocellular function during in vitro coculture: a mechanism of altered liver function in sepsis Infect Immun 49 1985 563-570
9. West M.A. Billiar T.R. Mazuski J.E. et al. Endotoxin modulation of hepatocyte secretory and cellular protein synthesis is mediated by Kupffer cells Arch Surg 123 1988 1400-1405
10. Billiar T.R. Curran R.D. Stuehr D.J. et al. An l-arginine dependent mechanism mediates Kupffer cell inhibition of hepatocyte protein synthesis in vitro J Exp Med 169 1989 1467-1472
11. Wang P. Ba B.F. Chaudry I.H. Hepatocellular dysfunction occurs earlier than the onset of hyperdynamic circulation during sepsis Shock 3 1995 21-26
12. Peck M.D. Alexander J.W. Survival of septic guinea pigs is influenced by vitamin E but not by vitamin C in enteral diets J Parenter Enteral Nutr 15 1990 433-436
13. Henderson A. Hayes P. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug Ann Pharmacother 28 1994 1086-1088
14. Fox E.S. Brower J.S. Bellezzo J.M. et al. N-acetylcysteine and α-tocopherol reverse the inflammatory response in activated rat kupffer cells J Immunol 158 1997 5418-5423
15. Betaller R. Brenner D. Hepatic stellate cells as a target for the treatment of liver fibrosis Sem Liv Dis 21 2001 437-451
16. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress Mol Aspects Med 21 2000 49-98
17. Kawada N. Seki S. Inoue M. et al. Effect of antioxidants resveratrol, quercetin, and N-acetylcysteine, on the function of cultured rat hepatic stellate cells and Kupffer cells Hepatology 27 1998 1265-1274
18. Schuppan D. Porov Y. Hepatic fibrosis: From bench to bedside J Gastroenterol Hepatol 17 Suppl 3 2002 S300-S305
19. Benyon R.C. Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells Sem Liv Dis 21 2001 373-384
20. Iredale J.P. Hepatic stellate cell behavior during resolution of liver injury Sem Liv Dis 21 2001 427-436
21. Sokol R.J. Devereaux M. Khandwala R. et al. Evidence for involvement of oxygen free radicals in bile acid toxicity to isolated rat hepatocytes Hepatology 17 1993 869-881
22. Sokol R.J. Devereaux M. Khandwala R.A. Effect of dietary lipid and vitamin E on mitochondrial lipid peroxidation and hepatic injury in the bile duct-ligated rat J Lipid Res 32 1991 1349-1357
23. Sokol R.J. McKim J.M. Jr. Goff M.C. et al. Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat Gastroenterology 114 1998 164-174
24. Yerushalmi B. Dahl R. Devereaux M.W. et al. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition Hepatology 33 2001 616-626
25. Benz C. Angermuller S. Kloters-Plachky P. et al. Effect of S-adenosylmethionine versus tauroursodeoxyhcolic acid on bile acid-induced apoptosis and cytolysis in rat hepatocytes Eur J Clin Invest 28 1998 577-583
26. Milkiewicz P. Roma M.G. Cardenas R. et al. Effect of tauroursodeoxycholate and S-adenosyl-L-methionine on 17β-estradiol glucuronide-induced cholestasis J Hepatol 34 2001 184-191
27. Gumpricht E. Devereaux M.W. Dahl R.H. et al. Glutathione status of isolated rat hepatocytes affects bile acid-induced cellular necrosis but not apoptosis Toxicol Appl Pharm 164 2000 102-111
28. Lin Y. Havinga R. Verkade H.J. et al. Bile acids suppress the secretion of very-low-density lipoprotein by human hepatocytes in primary culture Hepatology 23 1996 218-228
29. Lin Y. Havinga R. Schippers I.J. et al. Characterization of the inhibitory effects of bile acids on very-low-density lipoprotein secretion by rat hepatocytes in primary culture Biochem J 316 Pt 2 1996 531-538
30. Cales P. Apoptosis and liver fibrosis: antifibrotic strategies Biomed Pharmacother 52 1998 259-263
31. Van de Casteele M. Zaman Z. Zeegers M. et al. Blood antioxidant levels in patients with alcoholic liver disease correlate with the degree of liver impairment and are not specific to alcoholic liver injury itself Aliment Pharmacol Ther 16 2002 985-992
32. Leo M.A. Rosman A.S. Lieber C.S. Differential depletion of carotenoids and tocopherol in liver disease Hepatology 17 1993 977 -986
33. Yadav D. Hertan H.I. Schweitzer P. et al. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C Am J Gastroenterol 97 2002 2634-2639
34. Orlando R. Fragasso A. Lampertico M. et al. Silybin kinetics in patients with liver cirrhosis: comparative study between silybin-phosphatidylcholine complex and Silymarin Med Sci Res 18 1990 861-863
35. Orlando R. Fragasso A. Lampertico M. et al. Pharmacokinetic study of silybin-phosphatidylcholine complex in liver cirrhosis after multiple doses Med Sci Res 19 1990 827-828
36. Arora A.S. Gores G.J. The role of metals in ischemia/reperfusion injury of the liver Sem Liv Dis 16 1996 31-38
37. Sokol R.J. Devereaux M.W. O'Brien K. et al. Abnormal hepatic mitochondrial respiration and cytochrome C oxidase activity in rats with long-term copper overload Gastroenterology 105 1993 178-187
38. Sokol R.J. Twedt D. McKim J.M. et al. Oxidant injury to hepatic mitochondria in patients with Wilson's disease and Bedlington terriers with copper toxicosis Gastroenterology 107 1994 1788-1798
39. Sokol R.J. Antioxidant defenses in metal-induced liver damage Sem Liv Dis 16 1996 39-46
40. Sokol R.J. McKim J.M.Jr. Devereaux M.W. Alpha-tocopherol ameliorates oxidant injury in isolated copper-overloaded rat hepatocytes Pediatr Res 39 1996 259-263
41. Frage C.G. Oteiza P.I. Iron toxicity and antioxidant nutrients Toxicology 180 2002 23-32
42. Center S.A. Warner K.L. Copper, iron, and zinc concentrations in liver tissue from dogs with various liver disorders J Vet Intern Med 15 2001 295
43. Schultheiss P.C. Bedwell C.L. Hamar D. et al. Canine liver iron, copper, and zinc concentrations and association with histologic lesions J Vet Diagn Invest 14 2002 396-402
44. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis J Hepatol 28 1998 8-13
45. Pietrangelo A. Iron, friend or foe? "Freedom" makes the difference J Hepatol 32 2000 862-864
46. Paradis V. Mathurin P. Kollinger M. et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features J Clin Pathol 50 1997 401-406
47. Adams P.C. Iron overload in viral and alcoholic liver disease J Hepatol 28 Suppl 1 1998 19-20
48. Bonkovsky H.L. Iron as a comorbid factor in chronic viral hepatitis Am J Gastroenterol 97 2002 1-4
49. Carthew P. Edwards R.E. Dorman B.M. Hepatic fibrosis and iron accumulation due to endotoxin-induced haemorrhage in the gerbil J Comp Pathol 104 1991 303-311
50. Pietrangelo A. Gualdi R. Casalgrandi G. et al. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents J Clin Invest 95 1995a 1824-1831
51. Kent G. Volini F.I. Minick O.T. Effect of iron loading upon the formation of collagen in the hepatic injury induced by carbon tetrachloride Am J Pathol 45 1964 129-155
52. MacKinnon M. Clayton C. Plummer J. et al. Iron overload facilitates hepatic fibrosis in the rat alcohol/low-dose carbon tetrachloride model Hepatology 21 1995 1083-1088
53. Madra S. Mann F. Francis J.E. et al. Modulation by iron of hepatic microsomal and nuclear cytochrome p450, and cytosolic glutathione S-transferase and peroxidase in C57BL/10ScSn mice induced with polychlorinated biphenyls (Aroclor 1254) Toxicol Appl Pharmacol 136 1996 79-86
54. Dawson E.B. Albers J.H. McGanity W.J. The apparent effect of iron supplementation on serum selenium levels in teenage pregnancy Biol Trace Elem Res 77 2000 209-217
55. Sharma B.K. Bacon B.R. Britton R.S. et al. Prevention of hepatocytes injury and lipid peroxidation by iron chelators and α-tocopherol in isolated iron-loaded hepatocytes Hepatology 12 1990 31-39
56. Wagner B.A. Buettner G.R. Burns C.P. Vitamin E slows the rate of free radical-mediated lipid peroxidation in cells Arch Biochem Biophys 334 1996 261-267
57. Iqbal M. Rezazadeh H. Ansar S. et al. Alpha-tocopherol (vitamin E) ameliorates ferric nitrilotriacetate (Fe-NTA)-dependent renal proliferative response and toxicity: diminution of oxidative stress Hum Exp Toxicol 17 1998 163-171
58. Milchak L.M. Douglas Bricker J. The effects of glutathione and vitamin E on iron toxicity in isolated rat hepatocytes Toxicol Lett 126 2002 169-177
59. Muraoka K. Shimizu K. Sun X. et al. Flavonoids exert diverse inhibitory effects on the activation of NF-kappaB Transplant Proc 34 2002 1335-1340
60. Pietrangelo A. Borella F. Casalgrandi G. et al. Antioxidant activity of sylibinin in vivo during chronic iron overload in rats Gastroenterology 109 1995 1941-1949
61. Arrigo A.P. Gene expression and the thiol redox state Free Rad Biol Med 27 1999 936-944
62. Li Q. Verma I.M. NF-κβ regulation in the immune system Nature Rev 2 2002 725-734
63. Peristeris P. Clark B.D. Gatti S. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production Cell Immunol 140 1992 390-399
64. Houglum K. Venkataramani A. Lyche K. et al. A pilot study of the effects of d-α-tocopherol on hepatic stellate cell activation in chronic hepatitis C Gastroenterology 113 1997 1069-1073
65. Fox E.S. Leingang K.A. Inhibition of LPS-mediated activation in rat Kupffer cells by N-acetylcysteine occurs subsequent to NF-kappaB translocation and requires protein synthesis J Leukoc Biol 63 1998 509-514
66. Scheinman R.I. Cogswell P.C. Lofquist A.K. et al. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids Science 270 1995 283-286
67. Cole W.C. Prasad K.N. Contrasting effects of vitamins as modulators of apoptosis in cancer cells and normal cells: a review Nutr Cancer 29 1997 97-103
68. Droge W. Kinscherf R. Mihm S. et al. Thiols and the immune system Meth Enzy 251 1995 255-270
69. Meister A. On the biochemistry of glutathione In: Taniguchi N. Higashi R. Sakamoto Y. et al. editors. Glutathione centennial 1989 p. 3-21 Academic Press San Diego
70. Anderson M.E. Glutathione: an overview of biosynthesis and modulation Chem Biol Interact 111-112 1998 1-14
71. Meister A. Anderson M.E. Glutathione Ann Rev Biochem 52 1983 711-760
72. Aw T.K. Ooktens M. Kaplowitz N. Mechanism of inhibition of glutathione efflux by methionine from isolated rat hepatocytes Am J Physiol 14 1986 G354-G361
73. Fernandez-Checa J. Lu S.C. Ookhtens M. et al. The regulation of hepatic glutathione In: Tavoloni N. Berk P.D. editors Hepatic anion transport and bile secretion: physiology and pathophysiology 1992 p. 363-395 Marcel Dekker New York
74. Deleve L.D. Kaplowitz N. Glutathione metabolism and its role in hepatotoxicity Pharm Ther 52 1991 287-305
75. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis Free Rad Biol Med 27 1999 922-935
76. Lu S.C. Regulation of hepatic glutathione synthesis Sem Liv Dis 18 1998 331-343
77. Center S.A. Warner K.L. Erb H.N. Liver glutathione concentrations in dogs and cats with naturally occurring liver disease Am J Vet Res 63 2002 1187-1197
78. Kehrer J.P. Lund L.G. Cellular reducing equivalents and oxidative stress Free Rad Biol Med 17 1994 65-75
79. Akerboom T.P. Bilzer M. Sies H. The relationship of biliary glutathione disulfide efflux and intracellular glutathione disulfide content in perfused liver J Biol Chem 257 1982 4248-4252
80. Suzuki H. Sugiyama Y. Excretion of GSSG and glutathione conjugates mediated by MRP1 and cMOAT/MRP2 Sem Liv Dis 18 1998 359-376
81. Ballatori N. Truong A.T. Glutathione as a primary osmotic driving force in hepatic bile formation Am J Physiol 263 1992 G617-G624
82. Ballatori N. Truong A.T. Relation between biliary glutathione excretion and bile acid-independent bile flow Am J Physiol 38 1989 G22-G30
83. Niu N. Smith B.F. Addition of N-acetylcysteine to aqueous model bile systems accelerates dissolution of cholesterol gallstones Gastroenterology 98 1990 454-463
84. Wosiewitz U. Guldutuna S. Fischer H. et al. Pigment gallstone dissolution in vitro. Solubilization of brown bilirubinate and black polybilirubinate stone material by buffered solvents containing EDTA, bile salts, and reducing thiols Scan J Gastroentol 24 1989 373-380
85. Griffith O.W. Meister A. Origin and turnover of mitochondrial glutathione Proc Natl Acad Sci USA 82 1985 4668-4672
86. Griffith O.W. Meister A. Glutathione: interorgan translocation, turnover, and metabolism Proc Natl Acad Sci USA 76 1979 5606-5610
87. Fernandez-Checa J.C. Kaplowitz N. Garcia-Ruiz C. et al. Mitochondrial glutathione: importance and transport Sem Liv Dis 18 1998 389-401
88. Fernandez-Checa J.C. Kaplowitz N. et al. GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect Am J Physiol 273 1997 G7-G17
89. Rodrigues C.M.P. Fan G. Ma X. et al. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation J Clin Invest 101 1998 2790-2799
90. Rodrigues C.M.P. Fan G. Wong P.Y. et al. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production Mol Med 4 1998 165-178
91. Lieber C.S. Casini A. DeCarli L.M. et al. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon Hepatology 11 1990 165-172
92. Lieber C.S. Alcoholic liver disease: new insights in pathogenesis lead to new treatments J Hepatol 32 Suppl 2000 113-128
93. Lieber C.S. S-adenosyl-L-methionine: its role in the treatment of liver disorders Am J Clin Nutr 76 Suppl 2002 1183s-1187s
94. Garcia-Ruiz C. Morales A. Colell A. et al. Feeding S-adenosylmethionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes Hepatology 21 1995 207-214
95. Arias-Diaz J. Vara E. Garcia C. et al. S-adenosylmethionine protects hepatocytes against the effects of cytokines J Surg Res 62 1996 79-84
96. Chawla R.K. Watson W.H. Eastin C.E. et al. S-adenosylmethione deficiency and TNF-α in lipopolysaccharide-induced hepatic injury Am J Physiol 38 1998 G125-G129
97. Fernandez-Checa J.C. Colell A. Garcia-Ruiz C. S-adenosyl-L-methionine and mitochondrial reduced glutathione depletion in alcoholic liver disease Alcohol 27 2002 179-183
98. Shao L.E. Tanaka T. Gribi R. et al. Thioredoxin-related regulation of NO/NOS activities Ann N Y Acad Sci 962 2002 140-150
99. Powis G. Montfort W.R. Properties and biological activities of thioredoxins Annu Rev Biophys Biomol Struct 30 2001 421-455
100. Sen C.K. Packer L. Thiol homeostasis and supplements in physical exercise Am J Clin Nutr 72 Suppl 2000 653S-669S
101. Anderson M.E. Glutathione and glutathione delivery compounds Adv Pharmacol 38 1997 65-78
102. Anderson M.E. Luo J.-L. Glutathione therapy: from prodrugs to genes Sem Liv Dis 18 1998 415-429
103. Puri R.N. Meister A. Transport of glutathione, as γ-glutamylcysteinylglycyl ester, into liver and kidney Proc Natl Acad Sci USA 80 1983 5258-5260
104. Sies H. Glutathione and its role in cellular functions Free Radic Biol Med 27 1999 916-921
105. Watanabe A. Okada K. Shimizu Y. et al. Nutritional therapy of chronic hepatitis by whey protein (non-heated) J Med 31 2000 283-302
106. Micke P. Beeh K.M. Schlaak J.F. et al. Oral supplementation with whey proteins increases plasma glutathione levels of HIV-infected patients Europ J Clin Invest 31 2001 171-178
107. Olsson B. Johansson M. Gabrielsson J. Bolme P. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine Eur J Clin Pharmacol 34 1988 77-82
108. Sjodin K. Nilsson E. Hallberg A. et al. Metabolism of N-acetyl-l-cysteine Biochem Pharm 38 1989 3981-3985
109. Pastor A. Collado P.S. Almar M. Gonzalez-Gallego J. Antioxidant enzyme status in biliary obstructed rats: effects of N-acetylcysteine J Hepatol 27 1997 363-370
110. Corcoran G.B. Wong B.K. Role of glutathione in prevention of acetaminophen-induced hepatotoxicity by N-acetyl-L-cysteine in vivo: studies with N-acetyl-D-cysteine in mice J Pharm Exp Ther 238 1986 54-61
111. Pratt S. Ioannides C. Mechanism of the protective action of N-acetylcysteine and methionine against paracetamol toxicity in the hamster Arch Toxicol 57 1985 173-177
112. Harrison P.M. Wendon J.A. Gimson A.E. et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure N Engl J Med 324 1991 1852-1857
113. Nakano H. Boudjema K. Alexandre E. et al. Protective effects of N-Acetylcysteine on hypothermic ischemia-reperfusion injury of rat liver Hepatology 22 1995 539-545
114. Walsh T.S. Lee A. N-acetylcysteine administration in the critically ill Intensive Care Med 25 1999 432-434
115. Neuschwander-Tetri B.A. Bellezzo J.M. Britton R.S. et al. Thiol regulation of endotoxin-induced release of tumour necrosis factor alpha from isolated rat Kupffer cells Biochem J 320 1996 1005-1010
116. Suter P.M. Domenighetti G. Schaller M.D. et al. N-acetylcysteine enhances recovery from acute lung injury in man: a randomized, double-blind, placebo-controlled clinical study Chest 105 1994 190-194
117. Spies C. Giese C. Meier-Hellmann A. et al. The effect of prophylactically administered N-acetylcysteine on clinical indicators for tissue oxygenation during hyperoxic ventilation in cardiac risk patients Der Anesthesist 45 1996 343-350
118. Devlin J. Ellis A.E. McPeake J. et al. N-acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction Crit Care Med 25 1997 236-242
119. Heller A.R. Groth G. Heller S.C. et al. N-acetylcysteine reduces respiratory burst but augments neutrophil phagocytosis in intensive care unit patients Crit Care Med 29 2001 272-276
120. Koch T. Heller S. Heissler S. et al. Effects of N-acetylcysteine on bacterial clearance Eur J Clin Invest 26 1996 884-892
121. Smilkstein M.J. Knapp G.L. Kulig K.W. et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Engl J Med 319 1988 1557-1562
122. Droge W. Holm E. Role of cysteine and glutathione in HIV infection and other diseases associated with muscle wasting and immunological dysfunction FASEB J 11 1997 1077-1089
123. Breitkreutz R. Pittack N. et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials J Mol Med 78 2000 55-62
124. Kleinveld H.A. Demacker P.N. Stalenhoef A.F. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects Eur J Clin Pharmacol 43 1992 639-642
125. Oikawa S. Yamada K. Yamashita N. et al. N-acetylcysteine, a cancer chemopreventive agent, causes oxidative damage to cellular and isolated DNA Carcinogenesis 20 1999 1485-1490
126. Aruoma O.I. Halliwell B. Hoey B.M. et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid Free Radic Biol Med 6 1989 593-597
127. Kelly G.S. Clinical applications of acetylcysteine Alt Med Rev 3 1998 114-127
128. Bulger E.M. Maier R.V. Antioxidants in critical illness Arch Surg 136 2001 1201-1207
129. Bottiglieri S-adenosyl-L-methionine (SAMe): from the bench to the bedside-molecular basis of a pleiotrophic molecule Am J Clin Nutr 76 Suppl 2002 1151S-1157S
130. Friedel H.A. Goa K.L. Benfield P. S-adenosyl-L-methionine. A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism Drugs 38 1989 389-416
131. Chawla R.K. Bonkovsky H.L. Galambos J.T. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease Drugs 40 Suppl 3 1990 98-110
132. Mato J.M. Ortiz P. Pajares M.A. S-adenosylmethionine synthesis: molecular mechanisms and clinical implications Pharmacol Ther 73 1997 265-280
133. Mato J.M. Corrales F.J. Lu S.C. et al. S-adenosylmethionine: a control switch that regulates liver function FASEB J 16 2002 15-26
134. Mudd S.H. Poole J.R. Labile methyl balances for normal humans of various dietary regimens Metabolism 24 1975 721-735
135. Finkelstein J.D. Methionine metabolism in mammals J Nutr Biochem 1 1990 228-236
136. Martinez-Chantar M.L. Garcia-Trevijano E.R. Latasa M.U. et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury Am J Clin Nutr 76 Suppl 2002 1177S-1182S
137. Kinsell L.W. Harper H.A. Marton H.C. et al. Rate of disappearance from plasma of intravenously administered methionine in patients with liver damage Science 106 1947 589-590
138. Mato J.M. Corrales F. Martin-Duce A. et al. Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease. Part I. Biochemical implications Drugs 40 1990 58-64
139. Ansorena E. Garcia-Trevijano E.R. Martinez-Chantar M.L. et al. S-adenosylmethionine and methylthioadenosine are antiapoptotic in cultured rat hepatocytes but proapoptotic in human hepatoma cells Hepatology 35 2002 274-280
140. Watson W.H. Zhao Y. Chawla R.K. S-adenosylmethione attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor alpha Biochem J 342 1999 21-25
141. Pascale R.M. Simile M.M. DiMiglio M.R. et al. Chemoprevention of hepatocarcinogenesis: s-adenosyl methionine Alcohol 27 2002 193-198
142. Ponsoda X. Jover R. Gomez-Lechon M.J. et al. Intracellular glutathione in human hepatocytes incubated with S-adenosyl-L-methionine and GSH-depleting drugs Toxicology 70 1991 293-302
143. Lieber C.S. Role of S-adenosyl-L-methionine in the treatment of liver diseases J Hepatol 30 1999 1155-1159
144. Vendemiale G. Altomare E. Trizio T. et al. Effect of oral S-adenosyl-L-methionine on hepatic glutathione in patients with liver disease Scan J Gastroenteol 24 1989 407-415
145. Frezza M. Surrenti C. Manzillo G. et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind placebo controlled study Gastroenterology 99 1990 211-215
146. Pisi E. Marchesini G. Mechanisms and consequences of the impaired trans-sulphuration pathway in liver disease: part II. Clinical consequences and potential for pharmacological intervention in cirrhosis Drugs 40 1990 65-72
147. Frezza M. A meta-analysis of therapeutic trials with ademethionine in the treatment of intrahepatic cholestasis Ann Ital Med Int 8 Suppl 1993 48S-51S
148. Loguercio C. Nardi G. Argenzio F. et al. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease Alcohol 29 1994 597-604
149. Mato J.M. Camara J. Fernandez de Paz J. et al. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial J Hepatol 30 1999 1081-1089
150. Cabrero C. Martin Duce A. Ortiz P. et al. Specific loss of the high-molecular-weight form of S-adenosyl-L-methionine synthetase in human liver cirrhosis Hepatology 88 1988 1530-1534
151. Kakimoto H. Kawata S. Imai Y. et al. Changes in lipid composition of erythrocyte membranes with administration of S-adenosyl-L-methionine in chronic liver disease Gastroenterol Jpn 27 1992 508-513
152. Bray G.P. Tredger M. Williams R. S-adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models Hepatology 15 1992 297-301
153. Duce A.M. Ortiz P. Cabrero C. et al. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis Hepatology 8 1988 65-68
154. Wallace K. Center S.A. Hickford F. et al. S-adenosylmethionine treatment of Tylenol toxicity in a dog J Am Anim Hosp Assoc 38 2002 246-254
155. Webb C.B. Twedt D.C. Fettman M.J. S-Adenosylmethionine (SAMe) in a feline model of acetaminophen-induced oxidative damage J Feline Med Surg 5 2003 69-75
156. Colell A. Garcia-Ruiz C. Morales A. et al. Transport of reduced glutathione in hepatic mitochondria and mitoplasts from ethanol-fed treated rats: effect of membrane physical properties and S-adenosyl-L-methionine Hepatology 26 1997 699-708
157. Gonzalez-Correa J.A. De La Cruz J.P. Martin-Aurioles E. et al. Effects of S-adenosyl-L-methionine on hepatic and renal oxidative stress in an experimental model of acute biliary obstruction in rats Hepatology 26 1997 121-127
158. Jeon B.R. Lee S.M. S-adenosylmethionine protects post-ischemic mitochondrial injury in rat liver J Hepatol 34 2001 395-401
159. Lee Y.B. Lee S.M. Effect of S-adenosylmethionine on hepatic injury from sequential cold and warm ischemia Arch Pharm Res 23 2000 495-500
160. Dunne J.B. Piratvisuth T. Williams R. et al. Treatment of experimental ischemia/reperfusion injury with S-adenosylmethionine: evidence that donor pretreatment complements other regimens Transplantation 63 1997 500-506
161. Giudici G.A. Le Grazie C. Di Padova C. The use of ademethionine (SAMe) in treatment of cholestatic liver disorders: meta-analysis of clinical trials In: Mato J.M. Lieber C. Kaplowitz N. Caballero A. editors. Methionine metabolism: molecular mechanism and clinical implications 1992 p. 211-215 CSIC Press Madrid
162. Kaplotwitz N. Biochemical and cellular mechanisms of toxic liver injury Sem Liv Dis 22 2000 137-144
163. Tsukamoto H. Kim C.W. Luo Z.Z. et al. Role of lipid peroxidation in in vivo and in vitro models of liver fibrogenesis Gastroenterology 104 1993 A1012
164. Frezza M. Pozzato G. Chiesa L. et al. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methionine administration Hepatology 4 1984 274-278
165. Watson W.H. Chawla R.K. S-adenosylmethionine (SAMe) modulates biosynthesis of tumor necrosis factor a (TNF) in murine macrophage cells [abstract] Hepatology 26 1997-227
166. Schulze-Osthoff K. Bakker A.C. Vanhaesebroeck B. et al. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation J Biol Chem 267 1992 5317-5323
167. Simile M.M. Banni S. Agioni E. et al. 5′-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication J Hepatol 34 2001 386-394
168. Garcea R. Daino L. Pascale R. et al. Inhibition of promotion and persistent nodule growth by s-adenosyl-L-methionine in rat liver carcinogenesis: role of remodeling and apoptosis Cancer Res 49 1989 1850-1856
169. Muriel P. S-adenosyl-L-methionine prevents and reverses erythrocyte membrane alterations in cirrhosis J Appl Toxicol 13 1993 179-182
170. Lu S.C. Gukovsky I. Lugea A. et al. Role of S-adenosylmethionine in two experimental models of pancreatitis FASEB J 77 2002 56-58
171. Laudanno O.M. Cytoprotective effect of S-adenosylmethionine compared with that of misoprostol against ethanol, aspirin- and stress-induced gastric damage Am J Med 20 Suppl 5A 1987 43-47
172. Stramentinoli G. Ademethionine as a drug Am J Med 83 Suppl 1987 35-42
173. Center S.A. Warner K. Hoffman W.E. et al. Influence of s-adenosylmethionine on metabolic and morphologic hepatocellular features induced by chronic glucocorticoid administration in dogs [abstract] J Vet Intern Med 13 1999-253
174. Center S.A. Warner K. Hoffman W.E. Influence of SAMe on erythrocytes and liver tissue in healthy cats [abstract] J Vet Intern Med 14 2000 357
175. Horne D.W. Holloway R.S. Wagner C. Transport of S-adenosylmethionine in isolated rat liver mitochondria Arch Biochem Biophys 343 1997 201-206
176. Trainor D. Center S.A. Randolph J.F. et al. Urine sulfated and non-sulfated bile acids as a diagnostic test for liver disease in cats J Vet Intern Med 17 2003 145-153
177. Biourge V. Groff J.M. Fisher C. et al. Nitrogen balance, plasma free amino acid concentrations and urinary orotic acid excretion during long-term fasting in cats J Nutr 124 1994 1094-1103
178. Center S.A. Thompson M. Guida L. 3 Alpha-hydroxylated bile acid profiles in clinically normal cats, cats with severe hepatic lipidosis, and cats with complete extrahepatic bile duct occlusion Am J Vet Res 54 1993 681-688
179. Nakano H. Yamaguchi M. Kaneshiro Y. S-adenosyl-L-methionine attenuates ischemia-reperfusion injury of steatotic livers Transpl Proc 30 1998 3735-3736
180. Grattagliano I. Vendemiale G. Caraceni P. et al. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet J Nutr 130 2000 2131-2136
181. Abdelmalek M.F. Angulo P. Jorgensen R.A. et al. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study Am J Gastroenterol 96 2001 2711-2717
182. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study J Pediatr 136 2000 734-738
183. Sokol R. The sleeping giant has awakened J Pediatr 136 2000 711-713
184. Okan A. Astarcioglu H. Tankurt E. et al. Effect of ursodeoxycholic acid on hepatic steatosis in rats Dig Dis Sci 47 2002 2389-2397
185. Danson M.J. Dihydrolipoamide dehydrogenase: a "new" function for an old enzyme? Biochem Soc Trans 16 1988 87-89
186. Chen H.J. Chen Y.M. Chang C.M. Lipoyl dehydrogenase catalyzes reduction of nitrated DNA and protein adducts using dihydrolipoic acid or ubiquinol as the cofactor Chem Biol Int 140 2002 199-213
187. Reed L.J. Multienzyme complex Acc Chem Res 7 1974 40-46
188. Bustamente J. Lodge J.K. Marcocci L. et al. α-Lipoic acid in liver metabolism and disease Free Rad Biol Med 24 1998 1023-1039
189. Packer L. Witt E.H. Tritschler H.J. Alpha-lipoic acid as a biological antioxidant Free Rad Biol Med 19 1995 227-250
190. Han D. Handelman G. Marcocci L. et al. Lipoic acid increases de novo synthesis of cellular glutathione by improving cystine utilization Biofactors 6 1997 321-338
191. Zicker S.C. Hagen T.M. Joisher C. et al. Safety of long-term feeding of dl α-lipoic acid and its effect on reduced glutathione: oxidized glutathione ratios in beagles Vet Therap 3 2002 157-166
192. Gal E.M. Reversal of selective toxicity of (-)-alpha-lipoic acid by thiamine in thiamine-deficient rats Nature 207 1965 535
193. Packer L. Weber S.U. Rimbach G. Molecular aspects of tocotrienol antioxidant action and cell signalling J Nutr 131 2001 369S-373S
194. Ricciarelli R. Zingg J.-M. Azzi A. Vitamin E 80th anniversary: a double life, not only fighting radicals Life 52 2001 71-76
195. Brigelius-Flohe R. Kelly F.J. Salonen J.T. et al. The European perspective on vitamin E: current knowledge and future research Am J Clin Nutr 76 2002 703-716
196. Burton G.W. Traber M.G. Acuff R.V. et al. Human plasma and tissue α-tocopherol concentrations in response to supplementation with deuterated natural and synthetic vitamin E Am J Clin Nutr 67 1998 669-684
197. Azzi A. Stocker A. Vitamin E: non-antioxidant roles Prog Lipid Res 39 2000 231-255
198. Azzi A. Ricciarelli R. Zingg J.-M. Non-antioxidant molecular functions of α-tochopherol (vitamin E) FEBS Let 519 2002 8-10
199. Chojkier M. Houghum K. Lee K.S. et al. Long- and short-term D-alpha-tocopherol supplementation inhibits liver collagen alpha (I) gene expression Am J Physiol 275 1998 G1480-G1485
200. Ricciarelli R. Maroni P. Ozer N. et al. Age-dependent increase of collagenase expression can be reduced by alpha-tocopherol via protein kinase C inhibition Free Radic Biol Med 27 1999 729-737
201. Brigelius-Flohe R. Traber M.G. Vitamin E: function and metabolism FASEB J 13 1999 1145-1155
202. Von Herbay A. de Groot H. Hegi U. et al. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis, and Wilson's disease J Hepatol 20 1994 41-46
203. Canturk N.Z. Canturk Z. Utkan N.Z. et al. Cytoprotective effects of alpha tocopherol against liver injury induced by extrahepatic biliary obstruction East Afr Med J 75 1998 77-80
204. Deulofeu R. Pares A. Rubio M. et al. S-adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats Clin Sci 99 2000 315-320
205. Jewell D.E. Toll P.W. Wedeking K.J. et al. Effect of increasing dietary antioxidants on concentrations of vitamin E and total alkenals in serum of dogs and cats Vet Ther 1 2000 264-272
206. Twedt D.C. Webb C.B. Tetrick M.A. The effect of dietary vitamin E on the clinical laboratory and oxidant status of dogs with chronic hepatitis [abstract] J Vet Int Med 17 2003 418
207. Traber M.G. Rader D. Acuff R.V. et al. Vitamin E dose-response studies in humans with use of deuterated RRR-alpha-tochopherol Am J Clin Nutr 67 1998 669-684
208. Muggli R. Physiological requirements of vitamin E as a function of the amount and type of polyunsaturated fatty acid World Rev Nutr Diet 75 1994 166-168
209. Alexander D.W. McGuire S.O. Cassity M. et al. Fish oils lower rat plasma and hepatic, but not immune cell alpha-tocopherol concentration J Nutr 125 1995 2640-2649
210. McGuire S.O. Alexander D.W. Fritsche K.L. Fish oil source differentially affects rat immune cell alpha-tocopherol concentration J Nutr 127 1997 1388-1394
211. Bendich A. Machlin L.J. Safety of oral intake of vitamin E Am J Clin Nutr 48 1988 612-619
212. Kappus H. Diplock A. Tolerance and safety of vitamin E: a toxicological position report Free Rad Biol Med 13 1992 55-74
213. National Research Council Vitamin E: vitamin tolerance of animals 1987 National Academy Press Washington DC
214. Combs G.F. Vitamin E In: Combs G.F. editor The vitamins: fundamental aspects in nutrition and health 1992 p. 179-204 Academic Press San Diego
215. Rapola J.M. Virtamo J. Ripatti S. et al. Effects of alpha tocopherol and beta carotene supplements on symptoms, progression, and prognosis of angina pectoris Heart 79 1998 454-458
216. Jacob R.A. Sotoudeh G. Vitamin C function and status in chronic disease Nutr Clin Care 5 2002 66-74
217. Gerster H. High-dose vitamin C: a risk for persons with high iron stores? Internat J Vit Nutr Res 69 1999 67-82
218. Lynch S.R. Interaction of iron and other nutrients Nutr Rev 55 1997 102-110
219. Hoffman K.E. Yanelli K. Bridges K.R. Ascorbic acid and iron metabolism: alternations in lysosomal function Am J Clin Nutr 54 1991 1188S-1192S
220. Wellington K. Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders BioDrug 15 2001 465-489
221. Hammouda F.M. Ismail S.I. Hassan N.M. et al. Evaluation of the Silymarin content in Silybum marianum (L) Gaertn. Cultivation under different agricultural conditions Phytother Res 7 1993 90-91
222. Simanek V. Kren V. Ulrichova J. et al. Silymarin: what is in the name...? An appeal for a change of editorial policy Hepatology 32 2000 442-443
223. Saller R. Meier R. Brignoli R. The use of Silymarin in the treatment of liver diseases Drugs 61 2001 2035-2063
224. Lucena M.I. Andrade R.J. de la Cruz J.P. et al. Effects of Silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double blind, placebo-controlled clinical study Int J Clin Pharmacol Ther 40 2002 2-8
225. Jacobs B.F. Dennehy C. Ramirez G. et al. Milk thistle for the treatment of liver disease: a systematic review and meta-analysis Am J Med 113 2002 506-515
226. Flora K. Hahn M. Rosen H. et al. Silybum marianum for the therapy of liver disease Am J Gastroenterol 93 1998 139-143
227. Patrick D. Hepatitis C: Epidemiology and review of complementary/alternative medicine treatments Altern Med Rev 4 1999 220-238
228. Locher R. Suter P.M. Weyhenmeyer R. et al. Inhibitory action of Silibinin on low density lipoprotein oxidation Arzneimittelforschung 48 1998 236-239
229. Masini A. Ceccarelli D. Giovannini F. et al. Iron-induced oxidant stress leads to irreversible mitochondrial dysfunctions and fibrosis in the liver of chronic iron-dosed gerbils. The effect of silybin J Bioenergy Biomembr 32 2000 175-182
230. Pietrangelo A. Montosi G. Garuti C. et al. Iron-induced oxidant stress in nonparenchymal liver cells: mitochondrial derangement and fibrosis in acutely iron-dosed gerbils and its prevention by silybin Bioenerg Biomembr 34 2002 67-79
231. De Groot H. Dehmlow C. Rauen U. Tissue injury by free radicals and the protective effects of flavonoids Methods Find Exp Clin Pharmacol 18 Suppl B 1996 23-25
232. Sonnenbichler J. Mattersberger J. Rosen H. Stimulation of RNA synthesis in the rat liver and isolated hepatocytes by silybin, an antihepatotoxic agent from Silybum marianum Hoppee Seyler's Z Physiol Chem 357 1976 1171-1180
233. Machicao F. Sonnenbichler J. Mechanism of the stimulation of RNA synthesis in rat liver nuclei by silybin Hoppe Seylers Z Physiol Chem 358 1977 141-147
234. Sonnenbichler J. Zeti I. Mechanism of action of Silibinin. V. Effect of Silibinin on the synthesis of ribosomal RNA, mRNA, and tRNA in rat liver in vivo Hoppe Seylers Z Physiol Chem 365 1984 555-566
235. Sonnenbichler J. Goldberg M. Hane L. et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: non-response in hepatoma and other malignant cell lines Biochem Pharm 35 1986 538-541
236. Sonnenbichler J. Zetl I. Biochemical effects of the flavoligand silybin on RNA, protein and DNA synthesis of macromolecules in liver cells In: Cody V. Middleton E. Jr. Harborne J.B. editors, Plant flavanoids in biology and medicine: biochemical, pharmacological, and structure-activity relationships 1986 p. 319-331 Liss New York
237. 4-induced liver cirrhosis by silymarin Fundam Clin Pharmacol 3 1989 183-191
238. 4-chronic liver damage in rats Arch Med Res 28 1997 11-17
239. Boigk G. Stroedter L. Herbst H. et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats Hepatology 26 1997 643-649
240. Gonzalez-Correa J.A. de la Cruz J.P. Gordillo J. Effects of silymarin MZ-80 on hepatic oxidative stress in rats with biliary obstruction Pharmacology 64 2002 18-27
241. Fuchs E.C. Weyhenmeyer R. Weiner O.H. Effects of silibinin and of a synthetic analogue on isolated rat hepatic stellate cells and myofibroblasts Arzneimittelforschung 47 1997 1383-1387
242. Jia J.D. Bauer M. Cho J.J. et al. Antifibrotic effect of Silymarin in rat secondary biliary fibrosis is mediated by down regulation of procollagen α1(I) and TMP-1 J Hepatology 35 2001 392-398
243. Crocenzi F.A. Pellegrino J.M. Sanchez Pozzi E.J. et al. Effect of silymarin on biliary bile salt secretion in the rat Biochem Pharmacol 59 2000 1015-1022
244. +, and cytotoxicity in rat hepatocytes J Biol Chem 267 1992 6654-6663
245. Dehmlow C. Erhard J. de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of Silibinin Hepatology 23 1996 749-754
246. Saliou C. Rihn B. Cillard J. et al. Selective inhibition of NF-kappaB activation by the flavonoid hepatoprotector Silymarin in HepG2. Evidence for different activating pathways FEBS Lett 440 1998 8-12
247. Manna S.K. Mukhopadhyay A. Van N.T. et al. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis J Immunol 163 1999 6800-6809
248. Faulstich H. Jahn W. Wieland T. Silybin inhibition of amatoxin uptake in the perfused rat liver Arzneimittelforschung 30 1980 452-454
249. Zhao J. Sharma Y. Argarwal R. Significant inhibition by the flavonoid antioxidant Silymarin against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and Interleukin-1α expression in SENCAR mouse epidermis: implications in the prevention of stage 1 tumor promotion Mol Carc 26 1999 321-333
250. Zhao J. Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention Carcinogenesis 20 1999 2101-2108
251. Bartholomaeus A.R. Bolton R. Ahokas J.T. Inhibition of rat liver cytosolic glutathione S-transferase by silybin Xenobiotica 24 1994 17-24
252. Kroncke K.D. Ficker G. Meiers P.J. et al. α-Amanitin uptake into hepatocytes J Biol Chem 261 1986 12562-12567
253. El-Bahay C. Gerber E. Horbach M. et al. Influence of tumor necrosis factor-α and Silibinin on the cytotoxic action of α-Amanitin in rat hepatocyte culture Toxicol App Pharm 158 1999 253-260
254. Vogel G. Tuchweber B. Trost W. et al. Protection by Silibinin against Amanita phalloides intoxication in beagles Toxicol Appl Pharmacol 73 1984 355-362
255. Desplaces A. Choppin J. Vogel G. et al. The effects of Silymarin on experimental phalloidine poisoning Arzneimittelforschung 25 1975 89-96
256. Wu C.G. Chamuleau R.A. Bosch K.S. Protective effect of Silymarin on rat liver injury induced by ischemia Virchows Arch B Cell Pathol Incl Mol Pathol 64 1993 259-263
257. Kropacova K. Misurova E. Hakova H. Protective and therapeutic effect of Silymarin on the development of latent liver damage Radiats Biol Radioecol 38 1998 411-415
258. Chrungoo V.J. Singh K. Singh I. Silymarin mediated differential modulation of toxicity induced by carbon tetrachloride, paracetamol, and D-galactosamine in freshly isolated rat hepatocytes Indian J Exp Biol 35 1997 611-617
259. Muriel P. Garciapina T. Perez-Alvrez V. et al. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage J Appl Toxicol 12 1992 439-442
260. Szilard S. Szentgyorgyi D. Demeter I. Protective effect of Legalon in workers exposed to organic solvents Acta Med Hung 45 1988 249-256
261. Valenzuela A. Guerra R. Protective effect of the flavonoid silybin dihemisuccinate on the toxicity of phenylhydrazine on rat liver FEBS Lett 181 1985 291-294
262. Campos R. Garrido A. Guerra R. et al. Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver Planta Med 55 1989 417-419
263. Zuber R. Modriansky M. Dvorak Z. et al. Effect of silybin and its congeners on human liver microsomal cytochrome p450 activities Phytother Res 16 2002 632-638
264. Beckmann-Knopp S. Rietbrock S. Weyhenmeyer R. et al. Inhibitory effects of silibinin on cytochrome p-450 enzymes in human liver microsomes Pharm Tox 86 2000 250-256
265. Down W.H. Chasseaud L.F. Grundy R.K. Effect of silybin on the hepatic microsomal drug-metabolizing enzyme system in the rat Arzneimittelforsch 24 1974 1986-1988
266. Koch H. Insberger Z.G. Loslichkeitsparameter von Silybin, Silydianin und Silychristin Arch Pharm 313 1980 526-533 [in German]
267. Morazzani P. Montalbetti A. Malandrino S. Comparative pharmacokinetics of silipide and Silymarin in rats Europ J Drug Metabl Pharmacokinet 18 1993 289-297
268. Gatti G. Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers Int J Clin Pharmacol Ther 32 1994 614-617
269. Barzaghi N. Crema F. Gatti G. et al. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects Eur J Drug Metab Pharmacokinet 15 1990 333-338
270. Schandalik R. Gatti G. Perucca E. et al. Pharmacokinetics of silybin in bile following administration of silipide and Silymarin in cholecystectomy patients Arzneimittelforschung 42 1992 964-968
271. Lorenz D. Lucker P.W. Mennicke W.H. et al. Pharmacokinetic studies with silymarin in human serum and bile Methods Find Exp Clin Pharmacol 6 1984 655-661
272. Weyhenmeyer R. Mascher H. Birkmayer J. et. al. Study on dose-linearity of the pharmacokinetics of Silibinin diastereomers using a new stereospecific assay Int J Clin Pharmacol Ther Toxicol 30 1992 134-138
273. Flory P.J. Krug G. Lorenz D. Mennicke W.H. Studies on elimination of silymarin in cholecystectomized patients. I. Biliary and renal elimination after a single oral dose Planta Med 38 1980 227-237
274. Bulles H. Bulles J. Krumbiegel G. Mennicke W.H. Nitz D. Studies of the metabolism and excretion of silybin in the rat Arzneimittelforschung 25 1975 902-905
275. Rickling B. Hans B. Kramarczyk R. et al. Two high-performance liquid chromatographic assays for the determination of free and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with ultraviolet detection J Chromatogr B Biomed Appl 670 1995 267-277
276. Nassuato G. Iemmolo R.M. Strazzabosco M. et al. Effect of Silibinin on biliary lipid composition. Experimental and clinical study J Hepatol 12 1991 290-295
277. Nassuato G. Iemmolo R.M. Lirussi F. et al. Effect of Silybin on biliary lipid composition in rats Pharmacol Res Commun 15 1983 337-346
278. Lorenz D. Mennicke W.H. Behrendt W. Elimination of silymarin by cholecystectomized patients. 2. Biliary elimination after multiple oral doses Planta Med 45 1982 216-223
279. Parthasarathy S. Subbaiah P.V. Ganguly J. The mechanism of intestinal absorption of phosphatidylcholine in rats Biochem J 140 1974 503-508
280. Zierenberg O. Grundy S.M. Intestinal absorption of polyenephosphatidylcholine in man J Lip Res 23 1982 1136-1142
281. Galli C. Sirtori C.R. Mosconi C. et al. Prolonged retention of doubly labeled phosphatidylcholine in human plasma and erythrocytes after oral administration Lipids 27 1992 1005-1112
282. Navder K.P. Baraona E. Lieber C.S. Polyenylphosphatidylcholine decreases alcoholic hyperlipemia without affecting the alcohol-induced rise of HDL-cholesterol Life Sci 61 1997 1907-1914
283. Navder K.P. Baraona E. Leo M.A. et al. Oxidation of LDL in baboons is increased by alcohol and attenuated by polyenylphosphatidylcholine J Lipid Res 40 1999 983-987
284. Navder K.P. Baraona E. Lieber C.S. Dilinoleoylphosphatidylcholine protects human low density lipoproteins against oxidation Atherosclerosis 152 2000 89-95
285. Marathe G.K. Harrison K.A. Murphy R.C. et al. Role of oxidation in atherosclerosis: bioactive phospholipids oxidation products Free Rad Biol Med 28 2000 1762-1770
286. Lieber C.S. Leo M.A. Aleynik S.I. et al. Polyenyl-phosphatidylcholine decreases alcohol-induced oxidative stress in the baboon Alcohol Clin Exp Res 21 1997 375-379
287. Aleynik S.I. Leo M.A. Ma X. et al. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis J Hepatol 27 1997 554-661
288. Navder K.P. Baraona E. Lieber C.S. Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats J Nutr 127 1997 1800-1806
289. Baraona E. Zeballos G.A. Shoichet L. et al. Ethanol consumption increases nitric oxide production in rats, and its peroxynitrite-mediated toxicity is attenuated by polyenylphosphatidylcholine Alcohol Clin Exp Res 26 2002 883-889
290. Leiber C.S. Robins S.J. Li J. et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon Gastroenterology 106 1994 152-159
291. Aleynik S.I. Leo M.A. Takeshige U. et al. Dilinoleoylphosphatidylcholine is the active antioxidant of polyenylphosphatidylcholine J Investig Med 47 1999 507-512
292. Ma X. Zhao J. Lieber C.S. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression J Hepatol 24 1996 604-613
293. Gigliozzi A. Romeo R. Fraioli F. et al. Effect of s-adenosyl-L-methionine and dilinoleoyl-phosphatidylcholine on liver lipid composition and ethanol hepatotoxicity in isolated perfused rat liver Dig Dis Sci 43 1998 2211-2222
294. Cao Q. Mak K.M. Lieber C.S. DLPC decreases TGF-beta1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells Am J Physiol Gastrointest Liver Physiol 283 2002 G1051-G1061
295. Cao Q.I. Mak K. Lieber C.S. Dilinoleoylphosphatidylcholine (DLPC) decreases transforming growth factor-B1-mediated collagen production by rat hepatic stellate cells J Lab Clin Med 139 2002 202-210
296. Mi L.-J. Mak M.K. Lieber C.S. Attenuation of alcohol-induced apoptosis of hepatocytes in rat livers by polyenylphosphatidylcholine (PPC) Alcohol Clin Exp Res 24 2000 207-212
297. Poniachik J. Baraona E. Zhao J. et al. Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation J Lab Clin Med 133 1999 342-348
298. Holecek M. Mraz J. Koldova P. et al. Effect of polyunsaturated phosphatidylcholine on liver regeneration onset after hepatectomy in the rat Arzneimittelforschung 42 1992 337-339
299. Oneta C.M. Mak K.M. Lieber C.S. Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation J Lab Clin Med 134 1999 433-446
300. Aleynik S.I. Leo M.A. Ma X. Aleynik M.K. et al. Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver fibrosis J Hepatol 27 1997 554-561
301. Aleynik S.I. Leo M.A. Aleynik M.K. et al. Polyenylphosphatidylcholine protects against alcohol but not iron-induced oxidative stress in the liver Alcohol Clin Exp Res 24 2000 196-206
302. Aleynik M.K. Lieber C.S. Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome p4502E1 Biochem Biophys Res Commun 288 2001 1047-1051
303. Fassati P. Horejsi J. Fassati M. et al. Essential choline phospholipids and their effect on HbsAG and selected biochemical tests in cirrhosis of the liver Gas Lek Cesk 120 1981 56-60
304. Jenkins P.J. Portmann B.P. Eddleston A.L.W.F. et al. Use of polyunsaturated phosphatidylcholine in HbsAg negative chronic active hepatitis: results of prospective double-blind controlled trial Liver 2 1982 77-81
305. Bird G.L.A. Panos M.Z. Polson R. et al. Activity of polyunsaturated phosphatidylcholine in HbsAG negative active chronic hepatitis and acute alcoholic hepatitis Z Gastroenterol 29 Suppl 2 1991 21-24
306. Schuller-Perez A. Conzalez-San Martin F. Kontrollierte studie mit mehrfach ungesttigtem phosphatidylcholine im verglieich zu plazebo bei alkoholscher lebersteatose Med Welt 36 1985 517-521 [in German]
307. Singh N.D. Prasad R.C. A pilot study of polyunsaturated phosphatidyl choline in fulminant and subacute hepatic failure J Assoc Physicians India 46 1998 530-532
308. Niederau C. Strohmeyer G. Heintges T. et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial Hepatogastroenterology 45 1998 797-804
309. Kishi T. Takahashi T. Usui A. et al. Cytosolic NADPH-UQ reductase, the enzyme responsible for cellular ubiquinone redox cycle as and endogenous antioxidant in the rat liver Biofactors 9 1999 189-197
310. Ernster L. Dallner G. Biochemical, physiological and medical aspects of ubiquinone function Biochem Biophys Acta 1271 1995 195-204
311. Nohl H. Gille L. Staniek K. Endogenous and exogenous regulation of redox-properties of coenzyme Q Mol Aspects Med 18 1997 s33-s40
312. Xia L. Bjornstedt T. Nordman L.C. et al. Reduction of ubiquinone by lipoamide dehydrogenase. An antioxidant regenerating pathway Eur J Biochem 268 2001 1486-1490
313. Willis R.A. Anthony M. Loop R. et al. The effect of ethanol and/or food restriction on coenzyme Q in liver in rats Mol Aspects Med 18 1997 s205-s211
314. Yamamoto Y. Yamashita S. Fujisawa A. et al. Oxidative stress in patients with hepatitis, cirrhosis, and hepatoma evaluated by plasma antioxidants Biochem Biophys Res Commun 247 1998 166-170
315. Weis M. Mortensent S.A. Rassing M.R. et al. Bioavailability of four oral coenzyme Q10 formulations in healthy volunteers Mol Aspects Med 15 Suppl 1994 s273-s280
316. Weber C. Bysted A. Holmer G. Intestinal absorption of coenzyme Q10 administered in a meal or as capsules to healthy subjects Nutr Res 17 1997 941-945
317. Weber C. Bysted A. Holmer G. Coenzyme Q10 in the diet-daily intake and relative bioavailability Mol Aspects Med 18 1997 s251-s254
318. Beuers U. Spenglar U. Zwiebel F.M. et al. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease Hepatology 15 1992 603-608
319. Rudolph G. Endele R. Seen M. et al. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis Hepatology 17 1993 1028-1032
320. Mazzella G. Parini P. Bazzoli F. et al. Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis Dig Dis Sci 38 1993 896-902
321. Poupon R. Chazouilleres O. Poupon R.E. Chronic cholestatic diseases J Hepatol 32 2000 129-140
322. Trauner M. Graziadei I.W. Ursodeoxycholic acid in liver disease Aliment Pharmacol Ther 13 2002 979-995
323. Gores G.J. Miyoshi H. Botla R. et al. Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases Biochim Biophys Acta 1366 1998 167-175
324. Benz C. Angermuller S. Otto G. et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes Eur J Clin Invest 30 2000 203-209
325. Nicastri P.L. Diaferia A. Tartagni M. A randomised placebo-controlled trial of ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy Br J Obstet Gynaecol 105 1998 1205-1207
326. PLapenna D. Ciofani G. Festi D. et al. Antioxidant properties of ursodeoxycholic acid Biochem Pharm 64 2002 1661-1667
327. Setchell K.D.R. Rodrigues C.M.P. Clerici C. et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei Gastroenterology 112 1997 226-235
328. Poo J.L. Feldmann G. Erlinger S. et al. Ursodeoxycholic acid limits liver histologic alterations and portal hypertension induced by bile duct ligation in the rat Gastroenterology 102 1992 1752-1759
329. Peterson T.C. Slysz G. Isbrucker R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor stimulated proliferation is distinct from an effect by cyclic AMP Immunopharmacology 39 1998 181-191
330. Calmus Y. Gane P. Rouger P. et al. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid Hepatology 11 1990 12-15
331. Terasaki S. Nakanuma Y. Ogino H. et al. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy Am J Gastroenterol 86 1991 1194-1199
332. Hillaire S. Boucher E. Calmus Y. et al. Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes Gastroenterology 107 1994 781-788
333. Calmus Y. Arvieux C. Gane P. et al. Cholestasis induces major histocompatibility complex class 1 expression in hepatocytes Gastroenterology 102 1992 1371-1377
334. Calmus Y. Weill B. Ozier Y. et al. Immunosuppressive properties of chenodeoxycholic and ursodeoxycholic acids in the mouse Gastroenterology 103 1992 617-621
335. Yoshikawa M. Tsukii T. Matsumura K. et al. Immunomodulatory effects of ursodeoxycholic acid on immune response Hepatology 16 1992 358-364
336. Tanaka H. Makino I. Ursodeoxycholic acid-dependent activation of the glucocorticoid receptor Biochem Biophys Res Commun 188 1992 942-948
337. Mitsuyoshi H. Nakashima T. Inaba K. et al. Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase gene expression in cultured rat hepatocytes Biochem Biophys Res Commun 240 1997 732-736
338. Invernizzi P. Salzman A.L. Szabo V. et al. Ursodeoxycholate inhibits induction of NOS in human intestinal epithelial cells and in vivo Am J Physiol 273 1997 G131-G138
339. Kuerktshiev D. Subat S. Adler D. Immunomodulating effect of ursodeoxycholic acid therapy in patients with primary biliary cirrhosis J Hepatol 18 1993 373-377
340. Nishigaki Y. Ohnishi H. Moriwaki H. et al. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis Dig Dis Sci 41 1996 1487-1493
341. Funaoka M. Komatsu M. Toyoshima I. et al. Tauroursodeoxycholic acid enhances phagocytosis of the cultured rat Kupffer cell J Gastroenteol Hepatol 14 1999 652-658
342. Paumgartner G. Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited Hepatology 36 2002 525-531
343. Milkiewicz P. Mills C.O. Roma M.G. et al. Tauro UDC and S-adenosyl-L-methionine exert an additive ameliorating effect on taurolithocholate-induced cholestasis: a study in isolated rat hepatocyte couplets Hepatology 29 1999 471-476
344. Day D.G. Meyer D.J. Johnson S.E. et al. Evaluation of total serum bile acids concentration and bile acid profiles in healthy cats after oral administration of ursodeoxycholic acid Am J Vet Res 55 1994 1474-1478
345. Nicholson B.T. Center S.A. Randolph J.F. et al. Effects of oral ursodeoxycholic acid in healthy cats on clinicopathological parameters, serum bile acids and light microscopic and ultrastructural features of the liver Res Vet Sci 61 1996 258-262
346. Meyer D.J. Thompson M.B. Senior D.F. Use of ursodeoxycholic acids in a dog with chronic hepatitis: effects on serum hepatic tests and endogenous bile acid composition J Vet Intern Med 11 1997 195-197
347. Hofmann A.F. Pharmacology of ursodeoxycholic acid, an enterohepatic drug Scand J Gastroenterol 29 Suppl 204 1994 1-15
348. Rubin R.A. Kowalski T.E. Khandelwal M. Malet P.F. Ursodiol for hepatobiliary disorders Ann Intern Med 89 1994 1447-1454
349. Burk R.F. Hill K.E. Regulation of selenoproteins Annu Rev Nutr 13 1993 65-81
350. Burk R.F. Selenium, an antioxidant nutrient Nutr Clin Care 5 2002 75-79
351. Burk R.F. Hill K.E. Selenoprotein P. A selenium rich extracellular glycoproteins J Nutr 124 1994 1891-1897
352. Burk R.F. Early D.E. Hill K.E. et al. Plasma selenium in patients with cirrhosis Hepatology 27 1998 794-798
353. McClain C.J. Marsano L. Burk R.F. et al. Trace metals in liver disease Sem Liv Dis 11 1991 321-339
354. Prasad A.S. Rabbani P. Abbasil A. et al. Experimental zinc deficiency in humans Ann Intern Med 89 1978 483-490
355. Valle B.L. Falchuk K.H. The biochemical basis of zinc physiology Phys Rev 73 1993 79-118
356. Bray T.M. Bettger W.J. The physiological role of zinc as an antioxidant Free Rad Biol Med 8 1990 281-291
357. Zago M.P. Oteiza P.I. The antioxidant properties of zinc: interactions with iron and antioxidants Free Radic Biol Med 31 2001 266-274
358. Oteiza P.I. Olin K.L. Fraga C.G. et al. Zinc deficiency causes oxidative damage to proteins, lipids and DNA in rat testes J Nutr 125 1995 823-829
359. Oteiza P.I. Clegg M.S. Keen C.I. Short-term zinc deficiency affects factor-κB nuclear binding activity in rat testes J Nutr 131 2001 21-26
360. Rogers J.M. Lonnerdal B. Hurley L.S. et al. Iron and zinc concentrations and 59Fe retention in developing fetuses of zinc-deficient rats J Nutr 117 1987 1875-1882
361. Lonnerdal B. Dietary factors influencing zinc absorption J Nutr 130 2000 1378S-1383S
362. Hunt J.R. Hohnson P.E. Swan P.B. Dietary conditions influencing relative zinc availability from foods to the rat and correlations with in vitro measurements J Nutr 117 1987 1913-1923
363. Sullivan J.F. Jetton M.M. Burch R.E. A zinc tolerance test J Lab Clin Med 93 1979 485-492
364. Karayalcin S. Areasoy A. Uzunalimoglu O. Zinc plasma levels after oral zinc tolerance test in nonalcoholic cirrhosis Dig Dis Sci 33 1988 1096-1102
365. Antonow D.R. McClain C.J. Nutrition and alcoholism In: Tarter R.E. Thiel D.H. editors. Alcohol and the brain 1985 p. 81-120 Plenum Publishing New York
366. Dunn M.A. Blalock T.L. Cousins R.J. Minireview: metallothionein (42525A) Proc Soc Exp Biol Med 185 1987 107-119
367. Cousins R.J. Leinart A.S. Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin I FASEB J 2 1988 2884-2890
368. Vallee B.L. Wacker W.E.C. Bartholomay A.F. et al. Zinc metabolism in hepatic dysfunction: I. Serum zinc concentrations in Laennec's cirrhosis and their validation by sequential analysis N Engl J Med 255 1956 403-408
369. Giroux E. Schechter P.J. Shoun J. et al. Reduced binding of added zinc in serum of patients with decompensated hepatic cirrhosis Eur J Clin Invest 7 1977 71-73
370. Yoshida Y. Higashi T. Nouso K. et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis Acta Med Okayama 55 2001 349-355
371. Williams R.B. Chesters J.K. The effects of early zinc deficiency on DNA and protein synthesis in the rat B J Nutr 24 1970 1053-1059
372. 14C-labeled methionine into tissue proteins in rats J Nutr 99 1969 425-432
373. Chandra R.K. Au B. Single nutrient deficiency and cell-mediated immune responses. I. Zinc Am J Clin Nutr 33 1980 736-738
374. Rabbani P. Prasad A.S. Plasma ammonia and liver ornithine transcarbamylase activity in zinc deficient rats Am J Physiol 235 1978 E203-E206
375. Burch R.E. Williams R.V. Hahn H.K.J. et al. Serum and tissue enzyme activity and trace-element content in response to zinc deficiency in the pig Clin Chem 21 1975 568-577
376. Van der Rijt C.C. Schalm S.W. Schat H. et al. Overt hepatic encephalopathy precipitated by zinc deficiency Gastroenterology 100 1991 1114-1118
377. Baraldi M. Caselgrandi E. Borella P. et al. Decrease of brain zinc in experimental hepatic encephalopathy Brain Res 258 1982 170-172
378. Romero-Gomez M. Boza F. Garcia-Valdecasas M.S. et al. Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy Am J Gastroenterol 96 2001 2718-2723
379. Bresci G. Parisi G. Banti S. Management of hepatic encephalopathy with oral zinc supplementation: a long-term treatment Eur J Med 2 1993 414-416
380. Loomba V. Pawar G. Dhar K.L. et al. Serum zinc levels in hepatic encephalopathy Indian J Gastroenterol 14 1995 51-53
381. Reding P. Duchateau J. Bataille C. Oral zinc supplementation improves hepatic encephalopathy. Results of a randomized controlled trial Lancet 2 1984 493-495
382. Riggio O. Ariosto F. Merli M. et al. Oral zinc supplementation does not improve chronic hepatic encephalopathy. Result from a double blind crossover trial Dig Dis Sci 36 9 1991 1204-1208
383. Nakatani T. Tawaramoto M. Opare Kennedy D. et al. Apoptosis induced by chelation of intracellular zinc is associated with depletion of cellular reduced glutathione level in rat hepatocytes Chem Biol Interact 125 2000 151-163
384. Mackenzie G.G. Zago M.P. Keen C.L. et al. Low intracellular zinc impairs the translocation of activated NF-κB to the nuclei in human neuroblastoma IMR-32 cells J Biol Chem 277 2002 34610-34617
385. Nodera M. Yanagisawa H. Wada O. Increased apoptosis in a variety of tissues of zinc-deficient rats Life Sci 69 2001 1639-1649
386. Sen C.K. Packer L. Antioxidant and redox regulation of gene transcription FASEB J 10 1996 709-720
387. Ye B. Maret W. Vallee B. Zinc metallothionein imported into liver mitochondria modulates respiration Proc Natl Acad Sci USA 98 2001 2317-2322
388. Abel J. de Ruiter N. Inhibition of hydroxyl-radical-generated DNA degradation by metallothionein Toxicol Lett 47 1989 191-196
389. 2 with sulfhydryl groups in HL-60 cells: zinc-metallothionein and other sites Arch Biochem Biophys 334 1996 241-250
390. Giralt M. Gasull T. Hernandez J. et al. Effect of stress, adrenalectomy and changes in glutathione metabolism on rat kidney metallothionein content: comparison with liver metallothionein Biometals 6 1993 171-178
391. Zhou Z. Sun X. Lambert J. et al. Metallothionein-independent zinc protection from alcoholic liver injury Am J Pathol 160 2002 2267-2274
392. Maret W. Oxidative metal release from metallothionein via zinc-thiol/disulfide interchange Proc Natl Acad Sci USA 91 1994 237-241
393. Jiang L.J. Maret W. Vallee B.L. The glutathione redox couple modulates zinc transfer from metallothionein to zinc-depleted sorbital dehydrogenase Proc Natl Acad Sci USA 95 1998 3483-3488
394. Brewer G.J. Dick R.D. Schall W. et al. Use of zinc acetate to treat copper toxicosis in dogs J Am Vet Med Assoc 201 1992 564-568
395. Marchesini G. Fabbri A. Bianchi G. et al. Zinc supplementation and amino acid-nitrogen metabolism in patients with advanced cirrhosis Hepatology 23 1996 1084-1092
396. Riggio O. Ariosto F. Merli M. et al. Short-term oral zinc supplementation does not improve chronic hepatic encephalopathy. Results of a double-blind crossover trial Dig Dis Sci 36 1991 1204-1208
397. Couinaud C. Traitement de l'encephalopathie portosystemique aigue par le zinc Chirurgie 111 1985 575-579 [in French]
398. Weismann K. Christensen E. Dreyer V. Zinc supplementation in alcoholic cirrhosis Acta Med Scand 205 1979 361-366
399. Riggio O. Merli M. Capocaccia L. et al. Zinc supplementation reduces blood ammonia and increases liver ornithine transcarbamylase activity in experimental cirrhosis Hepatology 16 1992 785-789
400. Schrezenmeir J. de Vrese M. Probiotics, prebiotics, and synbiotics - approaching a definition Am J Clin Nutr 73 2 Suppl 2001 361S-364S
401. Liehr H. Heine W.D. Treatment of endotoxemia in galactosamine hepatitis by lactulose administered intravenously Hepatogastroenterology 28 1981 296-298
402. Spaeth G. Gottwald T. Specian R.D. et al. Secretory immunoglobulin A, intestinal mucin, and mucosal permeability in nutritionally induced bacterial translocation in rats Ann Surg 220 1994 798-808
403. Buddington R.K. Kelly-Quagliana K. Buddington K.K. et al. Non-digestible oligosaccharides and defense functions: lessons learned from animal models Br J Nutr 87 Suppl 2 2002 S231-S239
404. Albillos A. de la Hera A. Multifactorial gut barrier failure in cirrhosis and bacterial translocation: working out the role of probiotics and antioxidants J Hepatol 37 2002 523-526
405. Greve J.W. Gouma D.J. Buurman W.A. Bile acids inhibit endotoxin-induced release of tumor necrosis factor by monocytes: an in vitro study Hepatology 10 1989 454-458
406. Hattori Y. Murakami Y. Hattori S. et al. Ursodeoxycholic acid inhibits the induction of nitric oxide synthase Eur J Pharmacol 300 1996 147-150
407. Perez-Paramo M. Munoz J. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites Hepatology 31 2000 43-48
408. Chang C.S. Chen G.H. Lien H.C. et al. Small intestinal dysmotility and bacterial overgrowth in cirrhotic patients and spontaneous bacterial peritonitis Hepatology 28 1998 1187-1190
409. Pardo A. Bartoli R. Lorenzo-Zuniga V. et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis Hepatology 31 2000 858-863
410. Chiva M. Soriano G. Rochat I. et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis J Hepatol 37 2002 456-462
411. Schimple G. Pesendorfer P. Steinwender G. et al. Allopurinol and glutamine attenuate bacterial translocation in chronic portal hypertensive and common bile duct ligated growing rats Gut 39 1996 48-53
412. Schimpl G. Pesendorfer P. Steinwender G. et al. The effect of vitamin C and vitamin E supplementation on bacterial translocation in chronic portal hypertensive and common-bile-duct ligated rats Eur Surg Res 29 1997 187-194
413. Chang C.S. Chen G.H. Lien H.C. et al. Small intestinal dysmotility and bacterial overgrowth in cirrhotic patients and spontaneous bacterial peritonitis Hepatology 28 1998 1187-1190
414. Howe L.M. Boothe D.M. Boothe H.W. Endotoxemia associated with experimentally induced multiple portosystemic shunts in dogs Am J Vet Res 58 1997 83-88
415. Peterson S.L. Koblik P.D. Whiting P.G. et al. Endotoxin concentrations measured by a chromogenic assay in portal and peripheral venous blood in ten dogs with portosystemic shunts J Vet Intern Med 5 1991 71-74
416. Kuratsune H. Koda T. Kurahori T. The relationship between endotoxin and the phagocytic activity of the reticuloendothelial system Hepatogastroenterol 30 1983 79-82
417. Caplan M.S. Miller-Catchpole R. Kaup S. et al. Bifidobacterial supplementation reduces the incidence of necrotizing enterocolitis in a neonatal rat model Gastroenterology 117 1999 577-583
418. Kasravi F.B. Adawi D. Molin G. et al. Effect of oral supplementation of lactobacilli on bacterial translocation in acute liver injury induced by D-galactosamine J Hepatol 26 1997 417-424
419. Liehr H. Englisch G. Rasenack U. Lactulose, a drug with antiendotoxin effect Hepatogastroenterology 27 1980 356-360
420. Scevola D. Magliulo E. Trpin L. et al. Control of endotoxemia in liver disease by lactulose and paromomycin Boll Ist Sieroter Milan 58 1979 242-247
421. Mack D.R. Michail S. Wei S. et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression Am J Physiol 276 1999 G941-G950
422. Adawi D. Kasravi B. Molin G. et al. Effect of Lactobacillus supplementation with and without arginine on liver damage and bacterial translocation in an acute liver injury model in the rat Hepatology 25 1997 642-647
423. Oakey H.J. Harty D.W. Knox K.W. Enzyme production by lactobacilli and the potential link with infective endocarditis J Appl Bacteriol 78 1995 142-148
424. Rodriguez A.V. Baigori M.D. Alvarez S. et al. Phosphatidyl inositol-specific phospholipase C activity in Lactobacillus rhamnosus with capacity to translocate FEMS Microbiol Lett 204 2001 33-38
425. Buchman A.L. Glutamine: commercially essential or conditionally essential: A critical appraisal of the human data Am J Clin Nutr 74 2001 25-32
426. Reeds P.J. Burrin D.G. Glutamine and the bowel J Nutr 131 2001 2505S-2508S
427. Mazzaferro E. Hackett T. Wingfield W. et al. Role of glutamine in health and disease Comp Contin Ed Small Anim 22 2000 1094-1102
428. Ito A. Higashiguchi T. Effects of glutamine administration on liver regeneration following hepatectomy Nutrition 15 1999 23-28
429. Skullman S. Wiren M. Chu M. et al. Effects of graded glutamine intake on liver protein metabolism following partial hepatectomy Eur J Gastroenterol Hepatol 7 1995 881-886
430. Hong R.W. Round J.D. Helton W.S. et al. Glutamine preserves liver glutathione after lethal hepatic injury Ann Surg 215 1992 114-119
431. Denno R. Rounds J.D. Fans R. et al. Glutamine-enriched total parenteral nutrition enhanced plasma glutathione in the resting state J Surg Res 61 1996 35-38
432. Marks S.L. Cook A.K. Reader R. et al. Effects of glutamine supplementation of an amino acid-based purified diet on intestinal mucosal integrity in cats with methotrexate-induced enteritis Am J Vet Res 60 6 1999 755-763
433. Humbert B. Le Bacquer O. Nguyen P. et al. Protein restriction and dexamethasone as a model of protein hypercatabolism in dogs: effect of glutamine on leucine turnover Metabolism 50 2001 293-298
434. Bessman S.P. Bradley J.E. Uptake of ammonia by muscle. Its implications in ammoniagenic coma N Engl J Med 253 1955 1143-1147
435. Hod G. Chaouat M. Haskel Y. et al. Ammonia uptake by skeletal muscle in the hyperammonemic rat Eur J Clin Invest 12 1982 445-450
436. Lockwood A.H. McDonald J.M. Reiman R.E. et al. The dynamics of ammonia metabolism in man. Effects of liver disease and hyperammonemia J Clin Invest 63 1979 449-460
437. Felipo V. Butterworth R.F. Neurobiology of ammonia Prog Neurobiol 67 2002 259-279
438. Rudman D. DiFulco T.D. Galambos J.T. et al. Maximal rates of excretion and synthesis of urea in normal and cirrhotic subjects J Clin Invest 52 1973 2241-2249
439. Oppong K. Al-Mardini H. Thick M. et al. Oral glutamine challenge in cirrhotics awaiting liver transplantation: a psychometric and analyzed EEG study Hepatology 26 1997 870-876
440. Plauth M. Roske A.-E. Romaniuk P. et al. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration Gut 46 2000 849-855
441. Heyland D.K. Novak F. Drover J.W. et al. Should immunonutrition become routine in critically ill patients: a systematic review of the evidence JAMA 286 2001 944-953
442. Hayes K.C. Trautwein E.A. Taurine deficiency syndrome in cats Vet Clin North Am Small Anim Pract 19 1989 403-413
443. Edgar S.E. Hickman M.A. Marsden M.A. et al. Dietary cysteic acid serves as a precursor of taurine for cats J Nutr 124 1994 103-109
444. Morris J.G. Rogers Q.R. Kim S.W. et al. Dietary taurine requirement of cats is determined by microbial degradation of taurine in the gut Adv Exp Med Biol 359 1994 59-70
445. Huxtable R.J. Physiological actions of taurine Physiol Rev 72 1992 101-163
446. Hilgier W. Olson J.E. Brain ion and amino acid contents during edema development in hepatic encephalopathy J Neurochem 62 1994 197-204
447. Cordoba J. Gottstein J. Blei A.T. Glutamine, myo-inositol, and organic brain osmolytes after portacaval anastomosis in the rat: implications for ammonia induced brain edema Hepatology 24 1996 919-923
448. Cordoba J. Gottstein J. Blei A.T. Chronic hyponatremia exacerbates ammonia-induced brain edema in rats after portacaval anastomosis J Hepatol 29 1998 589-594
449. Raghavendra Rao V.L. Audet R.M. Butterworth R.F. Selective alternations of extracellular brain amino acids in relation to function in experimental portal-systemic encephalopathy: results of an in vivo microdialysis study J Neurochem 65 1995 1221-1228
450. Bremer J. The role of carnitine in cell metabolism In: De Simone C. Famularo G. Carnitine today 1997 p. 1-37 Landes Bioscience Austin (TX)
451. Goa K.L. Brogden R.N. l-carnitine: a preliminary review of its pharmacokinetics, and its therapeutic use in ischemic cardiac disease and primary and secondary carnitine deficiencies in relationship to its role in fatty acid metabolism Drugs 34 1987 1-24
452. Borum P.R. Carnitine function In: Borum P.R. Clinical aspects of human carnitine deficiency 1985 p. 157-164 Pergamon Press New York
453. Walter P. L-carnitine, a "vitamin-like" substance for functional food Ann Nutr Metab 44 2000 75-96
454. Rebouche C.J. Bosch E.P. Chenard C.A. et al. Utilization of dietary precursors for carnitine synthesis in human adults J Nutr 119 1989a 1907-1913
455. Gudjonsson H. Li B.U. Shug A.L. et al. In vivo studies of intestinal carnitine absorption in rats Gastroenterology 88 1985a 1880-1889
456. Guder W.G. Wagner S. The role of the kidney in carnitine metabolism J Clin Chem Clin Biochem 28 1990 347-350
457. Frohlich J. Seccombe D.S. Hahn P. et al. Effect of fasting on free and esterified carnitine levels in human serum and urine: correlation with serum levels free fatty acids and β-hydroxybutyrate Metabolism 27 1978 555-561
458. Cantoni C. L'Acqua V. Merlino P. Carnitine contents of meat and organs of slaughter house animals Arch Vet Ital 23 1972 412-417
459. Millington D.S. Dubay G. Dietary supplement L-carnitine: analysis of different brands to determine bioavailability and content Clin Res Regul Aff 10 1993 71-80
460. Bohmer T. Tissue levels of activated fatty-acids (acylcarnitines) and the regulation of fatty acid metabolism Biochim Biophys Acta 144 1967 259-270
461. Bremer J. Carnitine: metabolism and functions Physiol Rev 63 1983 1420-1480
462. Siliprandi N. Di Lisa F. Pieralisi G. et al. Metabolic changes induced by maximal exercise in human subjects following l-carnitine administration Biochim Biophys Acta 1034 1990a 17-21
463. Kerbey A.L. Randle P.J. Cooper R.X. et al. Regulation of pyruvate dehydrogenase in rat heart Biochem J 154 1976 327-348
464. Uziel G. Garvaglia B. DiDonato S. Carnitine stimulation of pyruvate dehydrogenase complex in isolated human skeletal muscle mitochondria Muscle Nerve 11 1988 720-724
465. Center S.A. Harte J. Watrous D. et al. The clinical and metabolic effects of rapid weight loss in obese pet cats and the influence of supplemental oral l-carnitine J Vet Intern Med 14 2000 598-608
466. Center S.A. Warner K.L. Randolph J.R. et al. Influence of L-carnitine on metabolic rate, fatty acid oxidation, body condition, and weight loss in obese cats 2001 World Veterinary Congress Vancouver, BC
467. Blanchard G. Paragon B.M. Milliat F. et al. Dietary L-carnitine supplementation in obese cats alters carnitine metabolism and decreases ketosis during fasting and induced hepatic lipidosis J Nutr 132 2002 204-210
468. Feller A.G. Rudman D. Role of carnitine in human nutrition J Nutr 118 1988 541-547
469. O'Connor J.E. Costell M. New roles of carnitine metabolism in ammonia cytotoxicity In: Grisolia S. Felipo V. Minana M.-D. editors. Cirrhosis, hepatic encephalopathy, and ammonium toxicity 1990 p. 182-195 Plenum Press New York
470. Ohtsuka Y. Clark D. Griffith O.W. Metabolic effects of carnitine and carnitine analogs In: Grisolia S. Felipo V. Minana M.-D. editors Cirrhosis, hepatic encephalopathy, and ammonium toxicity 1990 Plenum Press New York
471. Siliprandi N. Di Lisa F. Menabo R. Clinical use of carnitine: past, present and future In: Grisolia S. Felipo V. Minana M.-D. editors. Cirrhosis, hepatic encephalopathy, and ammonium toxicity 1990 p. 175-180 Plenum Press New York
472. Siliprandi N. Sartorelli L. Ciman M. et al. Carnitine: metabolism and clinical chemistry Clin Chim Acta 183 1989 3-12
473. Therrien G. Rose C. Butterworth J. et al. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portocaval shunted rat Hepatology 25 1997 551-556
474. Bellei M. Battelli D. Guarriero D.M. et al. Changes in mitochondrial activity caused by ammonium salts and the protective effect of carnitine Biochem Biophys Res Commun 158 1989 181-188
475. Hoppel C.L. Genuth S.M. Carnitine metabolism in normal-weight and obese human subjects during fasting Am J Physiol 238 1980 E409-E415
476. Jacobs G. Cornelius L. Keene B. et al. Comparison of plasma, liver, and skeletal muscle carnitine concentrations in cats with idiopathic hepatic lipidosis and in healthy cats Am J Vet Res 51 1990 1349-1351
477. Center S.A. Warner D. Corbett J. et al. Protein invoked by vitamin K absence in clotting times in clinically ill cats J Vet Intern Med 14 2000 292-297
478. Chan T.Y.K. Chan J.C.N. Tomlinson B. et al. Chinese herbal medicines revisited: a Hong Kong perspective Lancet 342 1993 1532-1534
479. Oka H. Fujiwara K. Oda T. et al. Xiao-chai-hu-tang and gui-zhi-fu-ling-wan for treatment of chronic hepatitis; recent advances in traditional medicine in East Asia In: Oda T. Needham J. Otsuka Y. Guo Bin I. editors Recent advances in traditional medicine in East Asia 1984 p. 232-237 Excerpta Medica Amsterdam
480. Gibo Y. Nakamura Y. Takahashi N. et al. Clinical study of sho-saiko-to therapy to the Japanese patients with chronic hepatitis type C (CH-C) Prog Med 14 1994 217-219
481. Oka H. Yamamoto A. Kuroki T. et al. Prospective study of chemoprevention of hepatocellular carcinoma with sho-saiko-to (TJ-9) Cancer 76 1995 743-749
482. Tajiri H. Kozaiwa K. Ozaki Y. et al. The study of the effect of sho-saiko-to on HbsAg clearance in children 8with chronic HBV infection and with abnformal liver function test Acta Paediatr Jpn 94 1990 1811-1815
483. Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma J Gastroenterol Hepatol 15 2000 D84-D90
484. Hirayama C. Okumura M. Tanikawa K. et al. A multicenter randomized controlled clinical trial of Sho-saiko-to in chronic active hepatitis Gastroenterol Jpn 24 1989 715-719
485. Geerts A. Rogiers V. Sho-saiko-to: the right blend of traditional Oriental medicine and liver cell biology Hepatology 29 1999 282-284
486. Tomlinson B. Chan T.Y.K. Chan J.C.N. et al. Toxicity of complementary therapies: an Eastern perspective J Clin Pharmacol 40 2000 451-456
487. Berk B.S. Chaya C. Benner K.C. et al. Comparison of herbal therapy for liver disease: 1996 versus 1999 Hepatology 30 1999 A478
488. Chitturi S. Farrell G.C. Herbal hepatotoxicity: an expanding but poorly defined problem J Gastroenterol Hepatol 15 2000 1093-1099
489. Kaplowitz N. Hepatotoxicity of herbal remedies: insights into the intricacies of plant-animal warfare and cell death Gastroenterology 113 1997 1408-1412
490. Stedman C. Herbal hepatotoxicity Sem Liv Dis 22 2002 195-206
491. Valla D. Benhamou J.P. Drug-induced vascular and sinusoidal lesions of the liver Clin Gastroenteol 2 1988 481-500
492. Larrey D. Hepatotoxicity of herbal remedies J Hepatol 26 1997 47-54
493. Ridker P.M. Ohkuma S. McDermott W.V. et al. Hepatic venocclusive disease associated with the consumption of pyrrolizidine-containing dietary supplements Gastroenterology 88 1985 1050-1054
494. Stickle F. Egerer G. Seitz H.K. Hepatotoxicity of botanicals Public Health Nutr 3 2000 113-124
495. Smith L.W. Culvenor C.C.J. Plant sources of hepatotoxic pyrrolizidine alkaloids J Nat Prod 44 1981 129-152
496. Mattocks A.R. Chemistry and toxicology of pyrrolizidine alkaloids 1986 Academic Press London
497. Schupke H. Hempel R. Peter G. et al. New metabolic pathways of α-lipoic acid Drug Met Disp 29 2001 855-862
498. Weber P. Bendich A. Machlin L.J. Vitamin E and human health: rationale for determining recommended intake levels Nutrition 13 1997 450-460
499. Morazzoni P. Bombardelli E. Silybum marianum (Carduus marianus) Fitoterapia 66 1995 3-42
500. Williams C.N. Al-Knawy B. Blanchard W. Bioavailability of four ursodeoxycholic acid preparations Aliment Pharmacol Ther 14 2000 1133-1139
501. Shay N.F. Mangian H. Neurobiology of zinc-influenced eating behavior J Nutr 130 2000 1493S-1499S
502. Hill A.S. Effects of lipoic acid in cats: pharmacokinetics, toxicity, and antioxidant activity [PhD dissertation] 2002 University of California at Davis Davis (CA)